Skip to main
NRSN

NRSN Stock Forecast & Price Target

NRSN Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeuroSense Therapeutics is in a favorable financial position with promising potential for its lead product candidate, PrimeC, in treating neurodegenerative diseases. Its promising results in pre-clinical and clinical studies for ALS, AD, and PD suggest a strong potential for future success, with a focus on targeting RNA regulatory pathways and utilizing a combination of FDA-approved drugs. However, financial constraints from its parent company, NeuroSense, could hinder the progress of PrimeC and more resources and funding are needed to advance the clinical trials and potentially bring PrimeC to market.

Bears say

NeuroSense Therapeutics is facing significant challenges in the development of its potential treatment for Alzheimer's disease and ALS. With an expected increase in the prevalence of these debilitating neurodegenerative diseases and a significant global healthcare burden, there is a high demand for effective treatments. However, the company may struggle with funding and regulatory hurdles, hindering its ability to bring PrimeC to market. As a financial analyst, this is a concerning outlook for the company's stock and its potential for future growth.

NRSN has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeuroSense Therapeutics Ltd (NRSN) Forecast

Analysts have given NRSN a Strong Buy based on their latest research and market trends.

According to 3 analysts, NRSN has a Strong Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeuroSense Therapeutics Ltd (NRSN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.